)
)
)
Sebastian BioPharma
March 02, 2026
Ballroom I C
Type: Company Presentation
Focus Area:
Oncology
Sebastian BioPharma is a preclinical oncology company developing tumor-targeted, multi-pathway therapeutics for colorectal cancer and other immunotherapy-resistant solid tumors. Our lead program uses a dual payload antibody–oligonucleotide conjugate approach designed to overcome tumor immune escape while reducing systemic toxicity, with expansion potential across additional solid tumors.
Year Founded:
2025
Lead Product in Development:
SBP-001, a tumor-targeted dual payload antibody–oligonucleotide conjugate designed to overcome immune resistance in colorectal cancer
Speakers
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
